Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$83.1MCash on Hand
CF+ Cash Runway
Follow PAHC by emailGet an email when PAHC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PAHC, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 4, 2026 ·
Earnings Reported Q1 fiscal 2027 net sales of $386.8 million, up 6%, and net income of $29.5 million, up 11%, and maintained full-year guidance of $1.55 billion to $1.60 billion in net sales. Shareholders elected three Class I directors and ratified PwC. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Declared a quarterly cash dividend of $0.12 per share on Class A and Class B common stock, payable December 16, 2026, to holders of record at the close of business on November 25, 2026. Form 8-K · SEC filing · Press release
Sep 18, 2026 ·
Shareholder vote Phibro's 2026 proxy sets its annual meeting for November 3, 2026, where stockholders will elect three Class I directors (Daniel M. Bendheim, Jonathan Bendheim and Sam Gejdenson) and ratify PricewaterhouseCoopers LLP as auditor for fiscal 2027. Form DEF 14A · SEC filing
Aug 26, 2026 ·
Annual report for the period ended Jun 30, 2026 Form 10-K · SEC filing
Aug 26, 2026 ·
Restructuring Phibro reported Q4 net sales of $396.7 million, up 5%, and fiscal 2026 net sales of $1,518.1 million, up 17%, with adjusted EBITDA of $255.0 million. It guided fiscal 2027 net sales to $1.55 billion to $1.60 billion and will close its Chicago Heights plant, affecting about 100 employees. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
PAHC holds $83.1M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PAHC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.